REVB 📈 Revelation Biosciences - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76135L1017
REVB: Immune system, Therapeutic products, Diagnostic solutions
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. Web URL: https://www.revbiosciences.com
Additional Sources for REVB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
REVB Stock Overview
| Market Cap in USD | 5m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2020-11-17 |
REVB Stock Ratings
| Growth 5y | -95.8% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -7649 |
| Analysts | 4/5 |
| Fair Price Momentum | 0.61 USD |
| Fair Price DCF | - |
REVB Dividends
No Dividends PaidREVB Growth Ratios
| Growth Correlation 3m | -76.7% |
| Growth Correlation 12m | -96.7% |
| Growth Correlation 5y | -97.5% |
| CAGR 5y | -90.86% |
| CAGR/Mean DD 5y | -1.26 |
| Sharpe Ratio 12m | -0.80 |
| Alpha | -124.00 |
| Beta | 1.14 |
| Volatility | 227.47% |
| Current Volume | 450.3k |
| Average Volume 20d | 6746.6k |
What is the price of REVB stocks?
As of January 10, 2025, the stock is trading at USD 0.58 with a total of 450,325 shares traded.
Over the past week, the price has changed by -11.72%, over one month by +28.89%, over three months by -27.91% and over the past year by -95.89%.
As of January 10, 2025, the stock is trading at USD 0.58 with a total of 450,325 shares traded.
Over the past week, the price has changed by -11.72%, over one month by +28.89%, over three months by -27.91% and over the past year by -95.89%.
Is Revelation Biosciences a good stock to buy?
No, based on ValueRay Analyses, Revelation Biosciences (NASDAQ:REVB) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -95.78 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of REVB as of January 2025 is 0.61. This means that REVB is currently overvalued and has a potential downside of 5.17%.
No, based on ValueRay Analyses, Revelation Biosciences (NASDAQ:REVB) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -95.78 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of REVB as of January 2025 is 0.61. This means that REVB is currently overvalued and has a potential downside of 5.17%.
Is REVB a buy, sell or hold?
Revelation Biosciences has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy REVB.
Revelation Biosciences has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy REVB.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for REVB stock price target?
According to ValueRays Forecast Model, REVB Revelation Biosciences will be worth about 0.7 in January 2026. The stock is currently trading at 0.58. This means that the stock has a potential upside of +17.24%.
According to ValueRays Forecast Model, REVB Revelation Biosciences will be worth about 0.7 in January 2026. The stock is currently trading at 0.58. This means that the stock has a potential upside of +17.24%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 12.8 | 2098.3% |
| Analysts Target Price | 12.8 | 2098.3% |
| ValueRay Target Price | 0.7 | 17.2% |